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ABSTRACT
Copy number changes and CpG methylation of vari-
ousgenesarehallmarksoftumordevelopmentbutare
not yet widely used in diagnostic settings. The
recently developed multiplex ligation-dependent
probe amplification (MLPA) method has increased
the possibilities for multiplex detection of gene
copy number aberrations in a routine laboratory.
Here we describe a novel robust method: the
methylation-specific MLPA (MS-MLPA) that can
detect changes in both CpG methylation as well as
copy number of up to 40 chromosomal sequences
in a simple reaction. In MS-MLPA, the ligation of
MLPA probe oligonucleotides is combined with
digestion of the genomic DNA–probe hybrid com-
plexes with methylation-sensitive endonucleases.
DigestionofthegenomicDNA–probecomplex,rather
than double-stranded genomic DNA, allowed the use
of DNA derived from the formalin treated paraffin-
embedded tissue samples, enabling retrospective
studies. To validate this novel method, we used MS-
MLPA to detect aberrant methylation in DNA samples
of patients with Prader–Willy syndrome, Angelman
syndrome or acute myeloid leukemia.
INTRODUCTION
Alterations of DNA methylation patterns have been recog-
nized as a common change in human cancers. Aberrant methy-
lation of normally unmethylated CpG-rich areas, also known
as CpG islands, which are located in or near the promoter
region of many genes, have been associated with transcrip-
tional inactivation of important tumor suppressor genes, DNA
repair genes and metastasis inhibitor genes (1,2). Therefore,
the detection of aberrant promoter methylation of cancer-
related genes may be essential for diagnosis, prognosis and/
or detection of metastatic potential of tumors. As the number
of genes known to be hypermethylated in cancer is large and
increasing, sensitive and robust multiplex methods for the
detection of aberrant methylation of promoter regions are
therefore, desirable. In addition, the amount of DNA available
for large-scale studies is often limited and of poor quality since
this DNA is isolated from the formalin treated, parafﬁn-
embedded tissues that have been stored at room temperature
for years.
Most current approaches for the detection of methylation
are based on the conversion of unmethylated cytosine residues
into uracil after sodium bisulphite treatment (3), which are
converted to thymidine during subsequent PCR. Thus, after
bisulphite treatment, alleles that were originally methylated
have different DNA sequences as compared with their
corresponding unmethylated alleles. These differences can
be exploited by several techniques, such as methylation-
speciﬁc PCR (MSP), restriction-digestion (COBRA), Methy-
light, direct sequencing, denaturing high-performance liquid
chromatography (DHPLC), nucleotide extension assays
(MS-SnuPE), methylation-speciﬁc oligonucleotide (MSO)
microarray and HeavyMethyl (3–10). However, most of
these methods are labor intensive and/or allow the study of
the methylation status of only one gene at a time. In addition,
most of these techniques are not suitable to study large num-
bers of parafﬁn-embedded tissue samples.
The recently developed multiplex ligation-dependent probe
ampliﬁcation (MLPA) technique (11) has been accepted as a
simple and reliable method for multiplex detection of copy
number changes of genomic DNA sequences using DNA sam-
ples derived from blood (12–16), amniotic ﬂuid (17) or tumors
(18). Here, we describe a rapid and easy method to apply
MLPA based method, methylation-speciﬁc MLPA (MS-
MLPA) for the detection of changes in methylation status
as well as copy number changes of up to 40 selected sequences
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doi:10.1093/nar/gni127in a reaction using only 20 ng of DNA. The general outline of
this method is shown in Figure 1. Similar to a conventional
MLPA assay (11) genomic DNA is ﬁrst denatured, followed
by the addition of MS-MLPA probes and a 16 h hybridization
step. Subsequently, this probe–DNA complex is simultane-
ously ligated and digested by methylation-speciﬁc enzymes.
If the CpG site is methylated, a normal MLPA product will be
detected. If the CpG site is not methylated, the DNA–probe
complex will be digested by the methylation-sensitive enzyme
and no ampliﬁcation product is formed. The MS-MLPA
method described here extends the MLPA method for multi-
plex copy number quantiﬁcation to a method for simultaneous
analysis of the copy number, as well as the methylation status
of up to 40 sequences in a simple reaction.
In this study, we demonstrate the use of the MS-MLPA
assay on DNA samples from Prader–Willy syndrome (PWS)
and Angelman syndrome (AS) patients and on DNA samples
derived from acute myeloid leukemia (AML) cell lines.
Furthermore, we show that this newly developed technique
can also be applied successfully to DNA derived from
parafﬁn-embedded tissues.
METHODS
DNA samples
DNA samples of 16 anonimized patients diagnosed with
PWS or AS were kindly provided by Ans van den Ouweland
(Erasmus MC, Rotterdam, The Netherlands).
Genomic DNA was isolated from 21 AML cell lines of
patients that had high blast counts. Tumor DNA samples,
either parafﬁn-embedded or fresh-frozen, were kindly pro-
vided by Petra Nederlof (Netherlands Cancer Institute,
NKI-AvL, Amsterdam, The Netherlands).
Methylated DNA was obtained by treating human genomic
DNA (Promega) with HhaI methylase (New England Biolabs)
in the presence of S-adenosylmethionine according to the
manufacturer’s instructions.
Paraffin-embedded DNA extraction
Slideswithasliceofparafﬁn-embeddedtissue (5mm · 5mm,
10mm of thickness) were heated for 15 min at 75 C to melt the
parafﬁn. The hot slides were placed in Xylol for 5 min. This
was repeated until the parafﬁn oil was completely dissolved.
The slides were then incubated for a period of 30 s in 99, 96
and 75% ethanol, tap water and ﬁnally placed in 1 M NaSCN
at 37 C overnight. The next day the slides were washed with
TEbuffer[10mMTris–HCl(pH8.5)and1mMEDTA]andair
dried. A few drops (20–40 ml) Proteinase K solution [2 mg/ml
recombinant Proteinase K (Roche) in 25 mM Tris–HCl
(pH 8.2)] were applied in the tissue. The tissue was transferred
to a 1.5 ml tube containing 100 ml Proteinase K solution and
incubated overnight at 37 C. After 20 min of incubation at
80 C to inactivate the Proteinase K, the tubes were centrifuged
for 10 min at 13000 rpm on an Eppendorf microcentrifuge.
Finally, 2 ml of the supernatant was used for each MS-MLPA
reaction.
MLPA probe design
The design of the MS-MLPA probes was performed as
described by Schouten et al. (11). However, each probe
used in this study for methylation quantiﬁcation analysis con-
tained one HhaI restriction site in the target recognition
sequence. In this study three probe mixtures were developed,
the P028 PWS/AS, the P041A and the P041B mixture. The
P028 PWS/AS probe mixture contains 25 probes speciﬁc for
most of the genes in the PWS/AS critical region of chromo-
some 15q11–q13 and two probes for genes that are located
Figure 1. Outline of the MS-MLPA procedure. An ordinary MLPA probe
harbors two oligonucleotides, one short synthetic and one long M13-derived
oligonucleotideandupto50probescanbeaddedtoeachMLPAreaction.Both
oligonucleotides contain universal primers sites. For each MLPA probe, the
M13 oligonucleotide is cloned in a M13-vector that contains stuffer sequence
that varies in length between the different probes. Subsequently, these long
M13-oligonucleotides are obtained by restriction-digestion from the M13
clones. For MS-MLPA, the probe designis similarto anordinaryMLPAprobe
except that the sequence detected by the MS-MLPA probe contains a recogni-
tionsequenceforHpaIIorHhaI.UpondigestionoftheDNA/MS-MLPAprobe
complex with one of the methylation-sensitive enzymes, probes of which the
recognition sequence is methylated will generate a signal. If the CpG site is
unmethylated the genomic DNA–MS-MLPA probe complex will be digested
and prevent exponential amplification and no signal will be detected after
fragment analysis.
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10 probes contained a HhaI recognition site. Furthermore, 14
control MLPA and MS-MLPA probes are included that are not
speciﬁc to genes on chromosome 15 (Supplementary Table 1).
The methylation mixture, P041A, contains a panel of 41
probes speciﬁc to 22 tumor suppressor genes (Supplementary
Table 2). The mixture contained for 19 genes in a single probe
that detects a HhaI sequence within the promoter region of
these genes. For VHL and CDKN2A, two probes are included.
For the promoter region of MLH1, three probes are included.
The remaining 15 probes in this mixture lack a HhaI sites in
their recognition sequence and serve as control probes. These
probes are used for quantiﬁcation of the methylation levels.
The P041B mixture contains MS-MLPA probes for the same
genes detected by the P041A mixture, except that these probes
recognize a different CpG site in the corresponding promoter
regions. Details on probe sequences, gene loci and chromo-
some locations can be found at www.mlpa.com.
MS-MLPA assay
MLPA reagents were obtained from MRC-Holland,
Amsterdam, The Netherlands (EK1 kit; www.mlpa.com).
Approximately 25 ng of genomic DNA in 5 ml of TE buffer
[10 mM Tris–HCl (pH 8.5) and 1 mM EDTA] was denatured
for 10 min at 98 C. SALSA MLPA buffer (1.5 ml) and
MS-MLPA probes (1 fmol each and 1.5 ml vol) were then
added and after incubation for 1 min at 95 C, were allowed
to hybridize to their respective targets for  16 h at 60 C. After
hybridization, the mixture was diluted at room temperature
with H2O and 3 ml Ligase buffer A to a ﬁnal volume of 20 ml
and then equally divided in two tubes. While at 49 C a mixture
of 0.25 ml Ligase-65 (MRC-Holland), 5 U HhaI (Promega)
and 1.5 ml Ligase buffer B in a total volume of 10 ml was added
to one tube. The second tube was treated identical except that
the HhaI enzyme was replaced with H2O. Simultaneous liga-
tion and digestion was then performed by incubation for
30 min at 49 C, followed by 5 min heat inactivation of the
enzymes at 98 C. The ligation products were PCR ampliﬁed
by the addition of 5 ml of this ligation mixture to 20 ml PCR
mixture containing PCR buffer, dNTPs, SALSA polymerase
and PCR primers (one unlabeled and one D4-labeled) at 60 C
as described by Schouten et al. (11).
Fragment and data analysis
Automated fragment and data analysis was performed by
exporting the peak areas to an excel based analysis program.
In brief, for copy number quantiﬁcation, every sample peak
area was divided by the nearest control peak areas. Relative
copy number was obtained by comparing this ratio with the
same ratio obtained from a control sample. Quantiﬁcation of
the methylation status of a particular CpG site was done by
dividing the peak area with the combined areas of the control
probes lacking a HhaI site. Finally, the relative peak area of
each target probe from the digested sample was compared with
those obtained from the undigested sample. Aberrant methy-
lation was scored when the calculated methylation percentage
was >10%. Any methylation percentages below this level were
regarded as background. All MS-MLPA reactions were
performed at least three times.
MSP and bisulphite sequencing
The DNA samples were converted by sodium bisulphite using
the EZ DNA Methylation Kit (Baseclear, The Netherlands)
following the manufacturer’s instructions. The modiﬁed DNA
was ampliﬁed using methylated and unmethylated speciﬁc
primers to amplify the same fragment within the promoters
of SNRPN and p15 as the respective MS-MLPA probes. The
PCR conditions were for reactions: a denaturation step at 95 C
for 5 min; 32 cycles at 95 C for 40 s, 65 C for 30 s, 72 C for
60 s. Finally, the PCR products were visualized on a 2.5%
agarose gel.
For SNRPN the following methylated primers used were
50-CGCGGTCGTAGAGGTAGGTTGGCGC and 50-GACA-
CAACTAACCTTACCCGCTCCATCGCG resulting in a
167 bp product.
For the unmethylated reaction the following primers were
50-GTATGTTTGTGTGGTTGTAGAGGTAGGTTGGTGT
and 50-CACCAACACAACTAACCTTACCCACTCCATCA-
CA resulting in a 180 bp product.
For MSP of p15 the following methylated primers used
were 50-GAAGGTGCGATAGTTTTTGGAAGTCGGCGC and
50-GACGATCTAAATTCCAACCCCGATCCGCCG resulting
in a 160 bp product. For the unmethylated reaction the
following primers were 50-GTGGAGAAGGTGTGATAGT-
TTTTGGAAGTTGGTGT and 50-CATCAACAATCTAAAT-
TCCAACCCCAATCCACCA resulting in a 169 bp product.
For bisulphite sequencing of the p15 gene the following
primers were used to amplify a 291 bp of the promoter region
including the target sequences recognized by the p15 MS-
MLPA probe: p15-forward 50-TAGGTTTTTTAGGAAGGA-
GAGAGTG-30 and p15-reverse 50-CCTAAAACCCCAAC-
TACCTAAATC. Subsequently, the nested forward primer
50-AGGAGAATAAGGGTATGTTTAGTGG-30 was used
for sequencing.
RESULTS
MS-MLPA with PWS and AS
To validate MS-MLPA, we used the P028 PWS/AS probe
mixture to analyze DNA samples of patients with PWS and
AS. These syndromes are distinct neurogenetic disorders,
which are characterized by deletions or uniparental disomy
resulting in aberrant expression of genes located in the
imprinted region on chromosome 15q11–q13. Absence of
a paternal contribution of chromosome 15q11–q13, due to
hemizygous deletion or uniparental disomy, results in PWS.
The absence of the corresponding maternal copy of the
same region causes AS (19). Among the probes in the P028
PWS/AS mixture seven probes are speciﬁc to the SNRPN
gene, which is located in the imprinting center. Five are
MS-MLPA probes containing a HhaI restriction site. If the
site is not methylated, HhaI digestion will prevent exponential
ampliﬁcation of the MS-MLPA probe (Figure 1). Patient with
AS due to uniparental disomy harbor two unmethylated alleles
and accordingly no MS-MLPA signal is observed (Figure 2a).
DNA from a patient with the PWS syndrome due to uni-
parental disomy shows no differences in peak areas of the
SNRPN speciﬁc MS-MLPA probes between the digested
and undigested sample DNA (Figure 2b), indicating that all
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50% reduction of the MS-MLPA signal, corresponding to the
presence of one methylated allele (Figure 2c).
Aberrant methylation in AML cell lines
AML is a heterogeneous disorder with respect to morphology
and chromosome aberrations detected in the leukemic cells.
Various genes known to be silenced by promoter methylation
have been analyzed in AML. Frequent aberrant promoter
methylation of the tumor suppressor genes p15
INK4b,
p16
INK4a and p73, has been described by different groups
(20–22). To evaluate MS-MLPA, we analyzed DNA samples
derived from 21 AML cell lines for promoter methylation
using probe mixture P041A that contains MS-MLPA probes
for 22 different genes (Supplementary Table 2). Of the 21
AML samples, frequent aberrant methylation of the genes
p15
INK4b and p73 occurred in nine (42.9%) and in ten
(47.6%) samples, respectively. Aberrant methylation was
also found in the following genes: IGSF4 (28.6%), TIMP-3
(23.8%), ESR1 (19.1%), FHIT (9.5%) and CDH13 (9.5%).
Two examples of a MS-MLPA proﬁle are shown in
Figure 3. In one sample of an AML cell line aberrant methy-
lation of the p15 (211 bp ampliﬁcation product) and the p73
(238 bp) gene was detected (Figure 3a). In addition, a decrease
in copy number of the MEN1 and HIC1 promoter is seen as
depictedbytheblackarrowsinthissample(Figure3b,193and
355 bp fragments). The other AML sample shows aberrant
methylation of several genes including TIMP-3 (142 bp),
KLK10 (184 bp), p15 (211 bp), p73 (238 bp), CDH13
(a)
(b)
(c)
(d)
Figure2.Detectionofthemethylationstatusoftheimprintingcenterinchromosome15byMS-MLPA.Approximately100ngofDNAfrompatientsdiagnosedwith
either PWS or AS and control DNA from healthy persons was subjected to MS-MLPA using the P028 PWS/AS probe mixture. Only a part of the capillary
electrophoresis (CE) patternis shown.Bluesignals correspondwith undigested DNA. Red signals correspond with the same samplesbut digested withHhaI. Black
arrows indicate three different HhaI sites in the promoter region of the SNRPN gene. The asterisks indicate the probe for which MSP was performed. Red arrows
indicate two HhaIsites; one withinthe chromosome15q11imprinted centerand one outside thatare not methylatedand serveas controlsfor properdigestion.Blue
arrowscorrespondwithotherprobeslocatedinthechromosome15q11regionwithoutaHhaIsitethatservesasacontrolforthecopynumberquantification.(a)CE-
pattern from an AS patient which has both alleles unmethylated therefore, after MS-MLPA no signal is generated from the MS-MLPA probes. (b) CE-pattern
generated from a PWS patient. Patients diagnosed with PWS due to uniparental disomy inherit only the maternally methylated allele in the promoter of the SNRPN
gene,thusbothallelesaremethylatedandthereforewillgenerateanormalsignal.(c)CE-patternfromcontrolDNA.Normalindividualshaveonemethylatedandone
unmethylated allele, thus a 50% reduction of the signal is seen. (d) MSP results on the three samples from above confirming the MS-MLPA results for the region
recognized by the 166 bp SNRPN promoter specific MS-MLPA probe.
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shown are the undigested MS-MLPA proﬁles that were used
for quantiﬁcation of the methylation levels (Figure 3b and d).
A summary of the MS-MLPA test results including SD is
shown in Supplementary Table 3. MS-MLPA experiments
have been performed at least three times.
The p15
INK4b gene is commonly inactivated in association
with promoter region hypermethylation involving multiple
sites in its 50-CpG island (23). In some gliomas and all of
the primary leukemias, this event occurs without epigenetic
alteration of the adjacent gene, p16
INK4a. In other tumors,
including lung, head, neck, breast, prostate and colon cancer,
inactivation of p15
INK4b occurs rarely and only with concomi-
tant inactivation of p16
(INK4a) (21,24,25). Indeed, we did not
observe hypermethylation of the p16
INK4a gene in any of the
21 AML samples.
To ensure that the disappearance of the MS-MLPA signals
was not caused by any other event than the HhaI endonuclease
treatment, we treated human genomic DNA (Promega) with
HhaI methylase. In this way the internal cytosine residue in de
HhaI recognition sequence (GCGC) becomes methylated. As
expected, MS-MLPA with 20 ng of HhaI methylase treated
DNA showed the presence of all MS-MLPA signals (data not
shown), conﬁrming that methylation of the sample DNA CpG
sites prevents HhaI endonuclease digestion of the sample
DNA–probe hybrids.
MSP and bisulphite sequencing
To validate the MS-MLPA ﬁndings in the DNA samples from
PWS and AS patients and DNA from AML samples, MSP was
carried out. The MSP primers were designed to amplify CpG
regions in the SNRPN and p15 genes. Each primer pair was
designed in order to contain at least two CpG sites including
the ones that are recognized by MS-MLPA. As shown in
Figures 2d and 4, all samples that showed methylation of
either SNRPN or p15 by MS-MLPA were also shown to be
methylated by MSP. For the p15 gene we also performed
(a) (c)
(b) (d)
Figure3.DetectionofaberrantmethylationpatternsinAMLcelllinesbyMLPAusingtheP041Aprobemixture.(a)CE-patternfromanAMLcelllineshowing50%
methylation of p15 (211 bp) and p73 (238 bp) genes (red dots). Total absence of all other MS-MLPA probes indicates 100% efficiency in the digestion reaction.
(b) CE-pattern from the same cell line [as shown in (a)] but without HhaI treatment, showing the undigested peak heights that were used for quantification of the
methylationlevels.WhencomparedtocontrolDNAsamples,areducedprobesignalspecificfortheMEN1andHIC1promotersisseenasshownbytheblackarrows,
indicatingadecreaseincopynumberofthesegenes[(b),193and355bpfragments].TheexpectednormalprobesignalsspecificfortheMEN1andHIC1promotersis
depictedbyblackarrowsin(d).(c)CE-patternfromanAMLcelllineshowingmethylationofseveralgenesincludingTIMP-3(142bp),KLK10(184bp),p15(211bp),
p73 (238 bp), CDH13 (247 bp), IGSF4 (319 bp) and ESR1 (373 bp) (red dots). (d) CE-pattern from the same cell line [as shown in (c)] but without HhaI treatment.
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by the p15 MS-MLPA probe. Bisulphite sequencing was per-
formed on three DNA samples: one control DNA sample
treated with HhaI methylase (Figure 5a), one DNA sample
of an AML cell line that was negative for p15 methylation
(Figure 5b) and one AML cell line that was positive for p15
methylation after MS-MLPA (Figure 5c).
The DNA sample that is treated with HhaI methylase
only the internal cytosine residue of the GCGC sequence
becomes methylated and thus is protected from bisulphite
conversion which is clearly seen in Figure 5a. All the other
CpG sites are converted (underlined). In the DNA sample that
is negative for p15 methylation all the CpG site are converted
(Figure 5b), whereas in the sample with positive p15 methy-
lation all the six CpG sites are protected including the CpG
Figure 4. MSP using specific primers to amplify the p15 promoter region of
two AML samples; one AML sample that showed positive methylation of the
p15 gene with MS-MLPA (POS) and one AML sample that was negative with
MS-MLPA (NEG). Also a MSP is included only with H2O as a control. As
expected a PCR product of 160 bp was detected with primers designed to
amplify methylated sequences (M) in the AML cell line positive for p15
methylation. In the AML cell line that was negative for p15 methylation with
MS-MLPAonlya169bpPCRproductwasdetectedindicatingthatthiscellline
was indeed not methylated for the p15 gene.
(a)
(b)
(c)
Figure 5. Bisulphitesequencing.Methylationstatusofp15promoterregionrecognizedbyMS-MLPAanalyzedbybisulphiteDNAsequencing.Threesampleswere
sequenced (a) One control DNA sample treated with HhaI methylase, (b) One DNA sample of an AML cell line that was negative for p15 methylation after MS-
MLPAand(c)OneAMLcelllinethatwaspositiveforp15methylationafterMS-MLPA.TheHhaIsiterecognizedbytheMS-MLPAprobeisdoubleunderlined.All
the CpG sites in this region are indicated (underlined). On top, part of the DNA sequence of the normal p15 sequence (without bisulphite treatment) is shown.
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(Figure 5c).
MS-MLPA on paraffin-embedded tissue
We next tested whether MS-MLPA could be used on DNA
derived from the formalin treated parafﬁn-embedded tissues.
DNA extracted from parafﬁn material is usually of poor qual-
ity and is notoriously difﬁcult to digest with restriction
endonucleases. Storage of tissues in formaldehyde solution
results in extensive crosslinking of proteins to other proteins
and to nucleic acids and in nucleic acid fragmentation (26,27).
Parafﬁn-embedding is commonly used and results in partial
denaturation of the DNA, making digestion of the sample
DNA very difﬁcult. In MS-MLPA, fragmentation of sample
DNA is not a problem, since the probes only require 50–60 bp
for hybridization and ligation. Besides, the sample DNA does
not need to be double-stranded as the digestion is performed
on the MS-MLPA DNA–probe complex. Indeed, identical
MS-MLPA results are obtained when using DNA derived
from parafﬁn-embedded tissue as compared with fresh-
frozen material prepared from the same tumors (Figure 6).
DISCUSSION
Here we describe a novel method, the MS-MLPA assay, for
the detection of aberrant methylation patterns of CpG islands
aswellascopynumberchangesofalargenumberofgenesina
simple reaction. To validate this method and to show the
linearity of response, we analyzed genomic DNA samples
of PWS and AS patients caused by uniparental disomy of
chromosome 15. The respective methylation status (0, 50
and 100% methylation) and copy number of the genes in
the 2 Mb 15q11–q13 PWS/AS region could simply be
identiﬁed by MS-MLPA. In addition, MS-MLPA was applied
to DNA samples from AML cell lines. In line with previous
reports,wedetectedfrequent aberrant promotermethylation of
the tumor suppressor genes p15 and p73 (20–22). For two
genes, SNRPN and p15, the methylation status of the CpG
sites recognized by the MS-MLPA probes were independently
conﬁrmed by MSP. To provide further evidence that the
MLPA results are in agreement with the observed methylation
status of this gene, we applied bisulphite sequencing of the
p15 promoter region.
The principle of MS-MLPA is almost similar to the previ-
ously described MLPA (11), except that the target sequences
detected by MS-MLPA probes contain a restriction site rec-
ognized by endonucleases such as HhaI or HpaII that are
sensitive to cytosine methylation of one CpG site in their
recognition sequence. Upon digestion with one of these
enzymes, a probe ampliﬁcation product will only be obtained
if the CpG site is methylated. The level of methylation was
determined by calculating the ratio of the relative peak area of
each target probe from the digested sample and from the
undigested sample.
Initially, in the process of developing MS-MLPA, the
genomic DNA was ﬁrst digested by CpG methylation-
sensitive restriction endonucleases and was then denatured
and hybridized with the MS-MLPA probes. Unmethylated
recognition sites for the restriction endonuclease are digested,
preventing the generation of probe ampliﬁcation products as
the two MLPA probe oligonucleotides bind to separate DNA
fragments. Although this alternative procedure yielded excel-
lent results, it has several drawbacks compared with the MS-
MLPAmethod presentedinthispaper.First,thelocationofthe
restriction endonuclease site is restricted to the vicinity of the
ligation site, whereas in MS-MLPA site can be anywhere in
the probe recognition sequence. Second, digestion had to be
performed in very small volumes, as the hybridization reaction
in MLPA is limited to a maximum sample volume of 5 ml.
(a) (b)
Figure 6. Comparison of MS-MLPA reactions performed on DNA obtained from the same breast tumors that were either paraffin-embedded or fresh-frozen.
Samples were analyzed using the P041A probe mixture. Indistinguishable MS-MLPA results were obtained with DNA from paraffin-embedded or fresh-frozen
tumor tissues. (a) CE-pattern from a MS-MLPA performed on DNA extracted from paraffin-embedded tissue. Red dots indicate methylation of one of the alleles
of the APC promoter (148 bp) and the ESR1 promoter (373 bp). (b) CE-pattern from a MS-MLPA performed on DNA from the same sample but derived from
fresh-frozen material, showing the same methylation pattern.
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order to be able to detect any copy number changes and to
quantify the methylation. Fourth, the salt conditions required
for restriction endonuclease digestion, prevented complete
denaturation of the genomic CpG islands by a simple heating
step. Finally, this alternative procedure did not allow analysis
of most DNA samples derived from parafﬁn-embedded tissue,
as the DNA could not be completely digested. This is probably
caused by partial denaturation of DNA that is extracted from
most parafﬁn-embedded tissues.
The MS-MLPA technique described here shows to be a
robust method and is even suitable for large-scale analysis
of DNA extracted from formaldehyde treated parafﬁn-
embedded tissue. In MS-MLPA, the ligation of the probes
while hybridized to their target sequence is combined with
simultaneous digestion of these complexes with methylation-
sensitive restriction endonucleases such as HhaI or HpaII. In
this study the HhaI digestion was more effective than HpaII.
Conditions of hybridization and ligation are nearly identical to
conventional MLPA reactions, only the temperature in the
ligation step had to be decreased from 54 to 49 C. HhaI
activity decreases at temperatures >50 C (data not shown).
Therefore, to ensure complete digestion of the DNA–MS-
MLPA probe complex, the ligation and digestion time had
to be extended from 15 to 30 min as compared with a con-
vential MLPA reaction. In addition, complete digestion was
also apparent by the disappearance of all MS-MLPA probes in
a MS-MLPA reaction whereas, incomplete digestion results
in general background peak signals of all MS-MLPA probes.
In MS-MLPA, genomic DNA is ﬁrst fully denatured, followed
by the formation of a hemimethylated DNA complex with the
MS-MLPA probes. Only methylation of the sample DNA
strand of this complex showed to be sufﬁcient to inhibit
HhaI methylation-sensitive digestion. This is in line with earl-
ier reports, which demonstrated that methylation of one strand
is sufﬁcient to block digestion by most methylation-sensitive
restriction endonucleases (28,29) (www.rebase.neb.com).
Similar to several other restriction endonucleases with a 4 nt
recognition site, HhaI also digests single-stranded DNA
although at a much lower rate. Several MS-MLPA probes
usedininitialexperimentscontainedanadditionalHhaIrecog-
nition sequence in the stuffer sequence. This stuffer sequence
is included in the M13-derived part of the MS-MLPA probes
in order to generate size differences between different probe
ampliﬁcation products. Digestion of single-stranded DNA by
HhaI is presumably dependent on the formation of secondary
structures that render the HhaI site temporarily double-
stranded. Although the digestion is performed at 49 C,
which limits the formation of secondary structures, several
probes were shown to be slowly digested at this additional
HhaI site (data not shown). In order to avoid false negative
results, these MS-MLPA probes were replaced by probes that
only harbor HhaI recognition sites within the hybridizing
sequences. In addition, a mutation or SNP very close or within
the recognition site of the restriction enzyme could inﬂuence
the digestion and might yield false positive results. Finally,
not all CpG’s within a promoter region are analyzed by
MS-MLPA, but only those CpG’s that block digestion of
methylation-sensitive endonucleases. When designing the
MS-MLPA probes, only one methylation-sensitive restriction
site should be present within the recognition sequence,
because not all CpG sites in a CpG island need to be methy-
lated to silence the transcription of a particular gene (30,31).
Thus, if a signal is generated from one MS-MLPA probe
but not from a second probe located elsewhere in the same
promoter, this indicates that the particular gene is methylated
and additional tests should be performed.
The sensitivity of the MS-MLPA probes for the methylation
status of sample DNA was demonstrated by the use of human
sample DNA that was methylated in vitro by HhaI methylase.
This resulted in ampliﬁcation products for all probes, as the
HhaI endonuclease is unable to cut methylated CpG sites.
Further, speciﬁcity of MS-MLPA was demonstrated by the
observation that all MS-MLPA probes that recognize a
HhaI site within a CpG island resulted in the absence of amp-
liﬁcation products after HhaI digestion of DNA samples from
healthy individuals (data not shown). In contrast, MS-MLPA
probes that recognize a HhaI site outside a CpG island showed
the presence of an ampliﬁcation product upon HhaI digestion
of the sample DNA–probe hybrids. This is in agreement with
the observation that CpG sites within CpG islands are
unmethylated whereas, the great majority of isolated CpG
sites are methylated in human DNA (32).
Several aspects contribute to the beneﬁt of MS-MLPA: (i) a
large number of genes can be studied using a minimum
amount of only 20 ng sample DNA; (ii) owing to its simple
procedure, large number of samples can be analyzed simulta-
neously; (iii) MLPA is quantitative and can discriminate
between methylation of one, both or none of the alleles;
and (iv) the simultaneous ligation and digestion reaction
enables MS-MLPA to be used on parafﬁn-embedded tissue
samples, because DNA degradation and partial DNA dena-
turation during embedding of the tissues or longtime storage
do not inﬂuence the results.
In recent years, the identiﬁcation of gene speciﬁc markers
forcancerdiagnosishasreceivedmuchattention.Althoughthe
attention is primarily focused on mRNA and protein levels in
tumor cells, the variation in expression level of many genes
could be caused by changes in copy number and/or methyla-
tion status of these genes or their regulators. In neuroblastoma,
e.g. certain genomic imbalances such as gain of 2p24 and 17q
and loss of heterozygosity at 1p36 have been associated with a
more aggressive phenotype (33,34). A recent study describes
the use of microarray chip technology for DNA based clinical
diagnostics in B cell chronic lymphocytic leukemia (B-CLL)
(35). In CLL, trisomy of chromosomes 12 and 19 and loss of
the 13q14 region, the p53, ATM and PTEN genes provide
important markers for tumor diagnosis (34). In addition to
genomic imbalances, epigenetic alterations might serve as
an important prognostic marker. In this regard it is of note
that recent studies imply that hypermethylation of the p16
gene in ovarian cancer and myeloma is associated with poorer
prognosis (36,37).
Due to its simplicity, the MS-MLPA method described here
couldserve as a powerfulscreening tool in tumor classiﬁcation
where often only limited amounts of DNA are available from
tissue slices that have been characterized by histological
examination. MS-MLPA can be used for the analysis of
both methylation as well as copy number changes in DNA
derived from blood samples of patients with various disorders
such as PWS, AS, Beckwith-Wiedemann syndrome and
FRAXE/FRAXA-mediated mental retardation.
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